NASDAQ:ENSC Ensysce Biosciences (ENSC) Stock Price, News & Analysis → Trump’s “Tax Free” Retirement Strategy (From Gold Safe Exchange) (Ad) Free ENSC Stock Alerts $0.79 -0.01 (-1.25%) (As of 03/28/2024 ET) Add Compare Share Share Today's Range$0.76▼$0.8150-Day Range$0.73▼$1.6352-Week Range$0.72▼$7.44Volume125,680 shsAverage Volume1.53 million shsMarket Capitalization$5.79 millionP/E RatioN/ADividend YieldN/APrice Target$11.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial Media Get Ensysce Biosciences alerts: Email Address Ensysce Biosciences MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside1,292.1% Upside$11.00 Price TargetShort InterestHealthy1.94% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.32Based on 3 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($2.50) to ($2.34) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.03 out of 5 stars 3.5 Analyst's Opinion Consensus RatingEnsysce Biosciences has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $11.00, Ensysce Biosciences has a forecasted upside of 1,292.1% from its current price of $0.79.Amount of Analyst CoverageEnsysce Biosciences has received no research coverage in the past 90 days. Previous Next 5.0 Short Interest Percentage of Shares Shorted1.94% of the float of Ensysce Biosciences has been sold short.Short Interest Ratio / Days to CoverEnsysce Biosciences has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Ensysce Biosciences has recently decreased by 34.38%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldEnsysce Biosciences does not currently pay a dividend.Dividend GrowthEnsysce Biosciences does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ENSC. Previous Next 2.4 News and Social Media Coverage News SentimentEnsysce Biosciences has a news sentiment score of 0.32. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.61 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Ensysce Biosciences this week, compared to 1 article on an average week.Search InterestOnly 7 people have searched for ENSC on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.MarketBeat Follows4 people have added Ensysce Biosciences to their MarketBeat watchlist in the last 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Ensysce Biosciences insiders have not sold or bought any company stock.Percentage Held by Insiders52.70% of the stock of Ensysce Biosciences is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 5.63% of the stock of Ensysce Biosciences is held by institutions. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Ensysce Biosciences are expected to grow in the coming year, from ($2.50) to ($2.34) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Ensysce Biosciences is -0.16, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Ensysce Biosciences is -0.16, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Gold Safe ExchangeTrump’s “Tax Free” Retirement Strategy Since 1924 — over one hundred years — the US dollar has lost nearly 18x its value. In other words, a dollar back then would buy $17.82 worth of goods in today's money. If you're planning on retiring any time soon…This poses a real problem.Protect your retirement savings from the inevitable devaluation of the dollar… About Ensysce Biosciences Stock (NASDAQ:ENSC)Ensysce Biosciences, Inc., a clinical-stage pharmaceutical company, engages in developing various prescription drugs for severe pain relief in opioid misuse, abuse, and overdose in the United States. It develops products using Trypsin Activated Abuse Protection platform, an abuse-resistant opioid prodrug technology; and Multi-Pill Abuse Resistance platform, an over-dose protection opioid prodrug technology. The company is developing PF614, a TAAP prodrug candidate of oxycodone for the treatment of acute or chronic pain; and PF614-MPAR, a combination product of PF614 and nafamostat for overdose protection against excessive oral ingestion, as well as an oral and inhalation drug product of nafamostat for use against coronaviral infections and other pulmonary diseases, such as cystic fibrosis. It is also developing PF614, an extended-release oxycodone-derivative which releases clinically effective oxycodone; PF8001 and PF8026 are extended and immediate-release prodrugs of amphetamine for ADHD medication abuse. The company is based in La Jolla, California.Read More ENSC Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ENSC Stock News HeadlinesMarch 18, 2024 | investorplace.comENSC Stock Earnings: Ensysce Biosciences Misses EPS, Beats Revenue for Q4 2023March 15, 2024 | finance.yahoo.comENSC Striding Toward Opioid ReplacementMarch 29, 2024 | Gold Safe Exchange (Ad)Trump’s “Tax Free” Retirement Strategy Since 1924 — over one hundred years — the US dollar has lost nearly 18x its value. In other words, a dollar back then would buy $17.82 worth of goods in today's money. If you're planning on retiring any time soon…This poses a real problem.March 15, 2024 | finanznachrichten.deEnsysce Biosciences, Inc.: Ensysce Biosciences Reports Fourth Quarter and Full Year 2023 Financial ResultsFebruary 21, 2024 | benzinga.comEnsysce Biosciences Stock (NASDAQ:ENSC), Short Interest ReportFebruary 21, 2024 | finance.yahoo.comEnsysce Biosciences Announces Successful Meeting with FDA for PF614-MPAR, a Next Generation Opioid with Overdose ProtectionFebruary 16, 2024 | finance.yahoo.comENSC: Investors Should Pay AttentionFebruary 15, 2024 | finanznachrichten.deEnsysce Biosciences, Inc.: Ensysce Biosciences Announces Publication of Clinical Bioequivalence ManuscriptMarch 29, 2024 | Gold Safe Exchange (Ad)Trump’s “Tax Free” Retirement Strategy Since 1924 — over one hundred years — the US dollar has lost nearly 18x its value. In other words, a dollar back then would buy $17.82 worth of goods in today's money. If you're planning on retiring any time soon…This poses a real problem.February 15, 2024 | finance.yahoo.comEnsysce Biosciences Announces Publication of Clinical Bioequivalence ManuscriptFebruary 13, 2024 | msn.comEnsysce Biosciences falls on exercise of warrants for $4.7M gross proceedsFebruary 13, 2024 | finance.yahoo.comEnsysce Biosciences, Inc. Announces Exercise of Warrants for $4.7 Million Gross ProceedsFebruary 6, 2024 | finanznachrichten.deEnsysce Biosciences, Inc.: Ensysce Biosciences Selected to Present at American Association of Pain Medicine Annual ConferenceFebruary 6, 2024 | finance.yahoo.comEnsysce Biosciences Selected to Present at American Association of Pain Medicine Annual ConferenceJanuary 31, 2024 | finance.yahoo.comEnsysce Biosciences Announces Positive End of Phase 2 Meeting with FDA for PF614 to Treat Severe PainJanuary 25, 2024 | finanznachrichten.deEnsysce Biosciences, Inc.: Ensysce Biosciences to Present Groundbreaking Oral Overdose Protection for Opioids at the 5th Annual NIH HEAL MeetingJanuary 25, 2024 | finance.yahoo.comEnsysce Biosciences to Present Groundbreaking Oral Overdose Protection for Opioids at the 5th Annual NIH HEAL MeetingJanuary 23, 2024 | seekingalpha.comEnsysce rallies 22% on FDA update for overdose-resistant opioidJanuary 23, 2024 | finance.yahoo.comOpioid Developer Ensysce Biosciences Stock Is Shooting Higher Today - Here's WhyJanuary 23, 2024 | finance.yahoo.comENSC Announces Major FDA DesignationJanuary 23, 2024 | finanznachrichten.deEnsysce Biosciences, Inc.: Ensysce Biosciences Announces FDA Breakthrough Therapy Designation Granted for PF614-MPARJanuary 23, 2024 | finance.yahoo.comEnsysce Biosciences Announces FDA Breakthrough Therapy Designation Granted for PF614-MPARJanuary 17, 2024 | msn.comEnsysce Biosciences files to sell common stock, warrantsJanuary 8, 2024 | finanznachrichten.deEnsysce Biosciences, Inc.: Ensysce Biosciences Issues 2024 Shareholder LetterJanuary 8, 2024 | finance.yahoo.comEnsysce Biosciences Issues 2024 Shareholder LetterDecember 19, 2023 | finance.yahoo.comEnsysce Biosciences Postpones Special Meeting of Stockholders to December 29, 2023December 14, 2023 | finance.yahoo.comEnsysce Biosciences Announces Key Efficacy Data for Lead AnalgesicSee More Headlines Receive ENSC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Ensysce Biosciences and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Today3/28/2024Next Earnings (Estimated)5/20/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:ENSC CUSIPN/A CIK1716947 Webensysce.com Phone858-263-4196FaxN/AEmployees7Year FoundedN/APrice Target and Rating Average Stock Price Target$11.00 High Stock Price Target$15.00 Low Stock Price Target$7.00 Potential Upside/Downside+1,292.1%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($5.06) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-10,610,000.00 Net Margins-476.29% Pretax Margin-476.29% Return on Equity-1,024.79% Return on Assets-262.37% Debt Debt-to-Equity RatioN/A Current Ratio0.69 Quick Ratio0.69 Sales & Book Value Annual Sales$2.23 million Price / Sales2.60 Cash FlowN/A Price / Cash FlowN/A Book Value($0.21) per share Price / Book-3.76Miscellaneous Outstanding Shares7,330,000Free Float3,467,000Market Cap$5.79 million OptionableNot Optionable Beta0.78 12 Stocks Corporate Insiders are AbandoningIf a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?Get This Free Report Key ExecutivesDr. D. Lynn Kirkpatrick Ph.D. (Age 67)President, CEO & Director Comp: $407.69kMr. David C. Humphrey CPA (Age 55)CFO, Secretary & Treasurer Comp: $342.06kMr. Geoffrey Birkett (Age 61)Chief Commercial Officer Comp: $313.29kDr. Jeffrey Millard Ph.d. (Age 48)Chief Operating Officer Dr. William K. Schmidt Ph.D. (Age 73)Chairman of Clinical Advisory Board & Chief Medical Officer Dr. Linda Pestano Ph.D. (Age 55)Chief Development Officer More ExecutivesKey CompetitorsNexImmuneNASDAQ:NEXIYumanity TherapeuticsNASDAQ:YMTXXenetic BiosciencesNASDAQ:XBIOKinetaNASDAQ:KAPulmatrixNASDAQ:PULMView All Competitors ENSC Stock Analysis - Frequently Asked Questions Should I buy or sell Ensysce Biosciences stock right now? 1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Ensysce Biosciences in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" ENSC shares. View ENSC analyst ratings or view top-rated stocks. What is Ensysce Biosciences' stock price target for 2024? 1 brokerages have issued twelve-month price objectives for Ensysce Biosciences' stock. Their ENSC share price targets range from $7.00 to $15.00. On average, they predict the company's stock price to reach $11.00 in the next twelve months. This suggests a possible upside of 1,292.1% from the stock's current price. View analysts price targets for ENSC or view top-rated stocks among Wall Street analysts. How have ENSC shares performed in 2024? Ensysce Biosciences' stock was trading at $1.06 at the start of the year. Since then, ENSC stock has decreased by 25.5% and is now trading at $0.7902. View the best growth stocks for 2024 here. Are investors shorting Ensysce Biosciences? Ensysce Biosciences saw a drop in short interest in the month of March. As of March 15th, there was short interest totaling 56,500 shares, a drop of 34.4% from the February 29th total of 86,100 shares. Based on an average daily volume of 1,440,000 shares, the short-interest ratio is currently 0.0 days. Approximately 1.9% of the shares of the company are sold short. View Ensysce Biosciences' Short Interest. When is Ensysce Biosciences' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, May 20th 2024. View our ENSC earnings forecast. When did Ensysce Biosciences' stock split? Ensysce Biosciences's stock reverse split on the morning of Friday, March 31st 2023. The 1-12 reverse split was announced on Friday, March 31st 2023. The number of shares owned by shareholders was adjusted after the market closes on Friday, March 31st 2023. An investor that had 100 shares of stock prior to the reverse split would have 8 shares after the split. Who are Ensysce Biosciences' major shareholders? Ensysce Biosciences' stock is owned by a number of retail and institutional investors. Top institutional investors include Concourse Financial Group Securities Inc. (0.00%). View institutional ownership trends. How do I buy shares of Ensysce Biosciences? Shares of ENSC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:ENSC) was last updated on 3/29/2024 by MarketBeat.com Staff From Our PartnersTrump’s “Tax Free” Retirement Strategy Gold Safe ExchangeDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsTop Project Outperforms BTC in 2023…Crypto 101 MediaMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceAI Cracks Open Largest Untapped Energy Reserve on EarthBanyan Hill PublishingThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading Academy“The Stock Market’s Bull Run is Far from Over” -BarronsVertical Research AdvisoryAI healthcare stock poised for 36,996% growth?Behind the Markets Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ensysce Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.